Future shifts to in vivo genome editing for a potential treatment strategy

1. BioIntel360 https://biointel360.com/

2. CRISPR has already shown promise in the field of biomedicine, initially by showing improvement in genome editing in bacteria and then quickly in humans and a wide range of other animals. While it will take some time before CRISPR becomes more well-known among scientists and ultimately among the general public, ushering in the CRISPR revolution. In the last ten years, CRISPR has advanced at an incredible rate, finding use in a variety of industries, including science, medicine, and agriculture. It has revolutionized the way we think about genetic engineering and opened the door to a range of previously unimaginable possibilities. Additionally, it has spurred debate and necessary discussions on the ethics of genome editing. With the promise of a wide range of applications, CRISPR has quickly become an invaluable tool in biotechnology and will undoubtedly continue to shape our future. Professor Doudna and her partner received the 2020 Nobel Prize as a consequence of their work. Base editors, prime editors, epigenome editors, RNA editors, and other CRISPR proteins have even undergone several iterations that increase their functionality and therapeutic potential. Future shifts to in vivo genome editing for a potential treatment strategy

3. It is pretty interesting to speculate about what the future of CRISPR might entail after reviewing its development over the previous ten years. Where are CRISPR's present applications advancing medical science? Where will the next phases of the development of CRISPR therapies occur? Both in vivo and ex vivo uses of CRISPR-based therapeutics are now being sought. The earliest in vivo applications primarily focused on rare indications, such as hereditary angioedema, transthyretin amyloidosis, and Leber's congenital amaurosis. The disease burden is large enough to support a riskier treatment strategy like CRISPR-mediated gene therapy at this time since the genetic causes are well understood, there is a well-established clinical development pathway, and the genetic causes are well understood. Early in vivo CRISPR initiatives also concentrated on disorders that started in organs including the brain, liver, eye, and blood disorders, and where it is possible to administer the CRISPR machinery.

4. Thanking You